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Abstract
As a common hematological malignant tumor, acute leukemia is believed to 
originate from a subpopulation of special cancer cells, named cancer stem cells. 
Cancer stem cells are recognized to be the main source of tumor origin, multidrug 
resistance, metastasis, and recurrence. Leukemic stem cells (LSCs) were first iden-
tified and confirmed to play an important role in the occurrence and development 
of leukemia. In this article, we summarize the following content: special markers 
and sorting methods for acute myeloid leukemia stem cells and the role of cancer 
stem cells in treatment resistance, metastasis and invasion, recurrence, and target 
treatment of acute leukemia.
Keywords: acute myeloid leukemia, cancer stem cells, leukemic stem cells,  
treatment resistance, metastasis
1. Introduction
Acute myeloid leukemia (AML) is a group of heterogeneous diseases char-
acterized by the uncontrolled proliferation of myeloid precursor cells and the 
replacement of normal hematopoiesis in the bone marrow. According to the 
latest survey, AML is a common cancer in adults and the second most common 
leukemia in children, with relatively higher rates observed in countries with high 
Human Development Index in North America, Oceania, and Europe [1]. The 
annual incidence rate of AML in the world is 2.25/100,000, and the incidence 
increases with age. The number is below 1/100,000 for people under 30 years of 
age and 17/100,000 for those above 75 years of age. Therefore, AML is actually a 
middle-aged and elderly disease, accounting for 80–90% of adult acute leukemia, 
but only accounts for 15–20% of children leukemia. Men have a higher incidence 
of AML than women, especially in North America, Oceania, Europe, and Asia. 
Epidemiology shows that environmental, occupational, and genetic factors are 
closely related to the pathogenesis of AML. Genetic changes in tumor cloning lead 
to a cascade of reactivity at the molecular level that cause abnormal proliferation 
and differentiation of malignant cells and inhibit normal hematopoiesis.
Tumorigenesis has been long known to resemble organogenesis and is a hetero-
geneous process involving many phenotypically and functionally different cells. 
The cancer stem cell (CSC) concept was first reported more than a century ago 
and refers to a very small subset of relatively quiescent cells in the tumor that are 
endowed with the ability to self-renew and differentiate into non-stem daughter 
cells that make the bulk of tumor [2]. Leukemic stem cells (LSCs) were first 
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identified and confirmed to play an important role in the occurrence and develop-
ment of leukemia. In 1994, Lapidot et al. reported that AML contains LSC. It is 
believed that only 0.1–1% cells have the ability to produce AML [3]. The researchers 
transplanted sublethal doses of CD34+CD38+ and CD34+CD38− subpopulations 
isolated from the bone marrow of a patient with AML into non-obese diabetic 
mice with severe combined immunodeficiency disease (NOD/SCID mice). After 
4–8 weeks, human AML cells isolated from the engrafted murine bone mar-
row expression both of CD34+CD38−. The recipient mouse, re-implanted with 
CD34+CD38− cells, could survive and pass to the next generation. The researchers 
also found CD34+CD38− cells can induce various subtypes of leukemia other than 
M3, thus indicating that this subpopulation of cells has stem cell-like strong self-
renewal and reproductive ability. In 1997, Bonnet et al. confirmed the presence of 
LSC in NOD/SCID mice [4]. Inoculation of 106 LSCs resulted in the formation of 
human AML in animals; this finding suggested that the “source of all evils” is LSC 
(Figure 1) [5]. Since then, the existence of LSC has been recognized, which is a 
significant milestone. The presence of LSC has been confirmed not only in hemato-
logical malignancies but also in some solid tumors.
Although LCSs were identified and thought to be the main cause of leukemia 
origin, recurrence, and drug resistance, there is still controversy regarding the 
origin of this distinct population [6]. Several hypotheses have been proposed with 
regard to the origin of LCS: (1) from hematopoietic stem cells (HSCs) [7]; (2) from 
partially differentiated hematopoietic progenitor cells [8]; (3) from blood vascular 
stem cells and granulocyte macrophage precursors (GMPs) [9–11]; and (4) from 
relatively mature leukemia cells [12]. Although the number of LSCs is small, LSCs 
have the same potential for self-renewal, multidirectional differentiation, and 
unlimited proliferation, resistance to cell death, multidrug resistance, metastasis, 
and recurrence. Because they can escape inhibition by most chemotherapeutic 
Figure 1. 
Comparison of the normal and AML human hematopoietic systems.
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drugs, LSCs in a relatively quiescent state can be latent for a long time. Once the 
conditions are appropriate, such as a certain stimulus into the cell cycle, they can 
escape the immune surveillance of the body, thus showing unlimited proliferation. 
Therefore, relevant research and analysis on the biological characteristics of LSCs 
may provide new ideas for therapeutic regimens. The discovery of LSCs has broad-
ened the treatment of leukemia, and targeted therapy of related signaling pathways 
and niche may become a new research hotspot.
2. Expression of special surface markers in LSCs
Bonnet et al. revealed that the CD34+CD38− subpopulation is similar to normal 
HSCs with surface markers and can be used to identify cells with unlimited pro-
liferation and differentiation in AML [4]. Subsequent studies have shown that the 
surface markers of LSCs are extremely complex and vary from person to person. 
Previous experiments have demonstrated that in some cases, subpopulations of 
cells with different phenotypes have LSC activity [13–15]. CD34 and CD38 are no 
longer specific markers that define LSCs. Recent studies have identified various new 
markers such as CLL-1, CD96, TIM3, CD47, CD32, and CD25. The current study 
summarizes some of the specific markers expressed by LSCs (Table 1) [16] and has 
been utilized to successfully validate LSCs in recent clinical trials [17].
2.1 CLL-1
C-type lectin domain family 12 member A (CLL1, also known as CLEC12A)-
positive cells show high tumorigenicity in immunodeficient mice, indicating that 
this cell subpopulation has the characteristics of LSCs. Moreover, the side popula-
tion cells enriched in LSCs isolated by flow cytometry from patients with AML also 
express CLL-1 [18]. Jiang et al. have reported that CLL1-antibody-drug conjugate 
(CLL1-ADC) could become an attractive target therapy for AML [19]. The use of a 
Marker Expression on LSC Reference
CD34 +/− [4, 13]
CD38 +/− [4, 12, 13]
CD90 −/+ [16]
CD123 ++ [16, 22]
CD45RA + [15]
CD33 ++ [90, 91]
CD13 ++ [15]
CD44 ++ [15]
CLL-1 + [17, 18]






Summary of cell surface marker expression on AML LSCs.
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DNA-binding payload in CLL1-ADC is critical because such a payload affords the 
ADC the ability to kill both proliferative and quiescent cells, thus making CLL1-
ADC a very compelling candidate for the treatment of patients with AML.
2.2 CD96
CD96 is a member of the immunoglobulin superfamily, a transmembrane 
glycoprotein, and a T-cell surface-specific receptor 6. By using blood samples from 
55 patients with AML, Du et al. found that CD96 (>10%)-enriched patients showed 
a poor response to chemotherapy [20]. Of note, CD96 was proved to be an efficient 
identical marker of LSCs in CD34+CD38− groups.
2.3 CD44
CD44 is a surface glycoprotein and a receptor for hyaluronic acid, which is 
mainly involved in cell-cell interaction, adhesion, and migration [16]. CD44+ 
cancer cells show higher sphere-forming ability and treatment resistance. CD44 is 
not only a special marker of LSC, but it is also a key regulator of LSC function that 
is essential for homing of LSCs to microenvironmental niches and for maintaining 
LSCs in a primitive state.
2.4 CD123 (IL3Rα)
Approximately 45% of AML cells that overexpress CD123 have higher prolifera-
tive activity and are more tolerant to apoptotic stimulation. Clinical studies have 
also demonstrated patients overexpressing CD123 usually have a poor prognosis. 
Williams et al. found that NK-92 preferentially inhibits leukemic stem cells com-
pared with bulk leukemia cells [21]. NK-92 combined with the anti-CD123 anti-
body, 7G3, enhanced survival in a primary AML xenograft model when compared 
with control arms. Some other IL3R antibodies (DT388IL3, CSL362, and MGD006) 
can significantly prolong the survival rate of patients with AML [22, 23].
2.5 CD47
CD47 is a transmembrane glycoprotein that is widely expressed in human 
tissues. CD47 also functions as a marker of “self” on host cells within an organism. 
When expressed, CD47 binds to SIRPα on the surface of circulating immune cells 
to deliver an inhibitory “don’t eat me” signal [24]. Higher expression of CD47 has 
been demonstrated in LSCs [25, 26]. Anti-CD47 antibody treatment has also been 
shown to act synergistically with cytarabine (Ara-C) chemotherapy in a model of 
AML. While Ara-C effectively eliminated TSP-1 cancer cells in the proliferative 
phase, anti-CD47 antibodies were putatively able to target quiescent LSCs that were 
not susceptible to Ara-C treatment but highly expressed CD47 [27].
2.6 CD25 and CD32
Saito et al. conducted microarray analysis and found that CD25 and CD35 
were expressed on quiescent LSCs, but not on HSCs [28]. The activation of CD25, 
namely IL2Rα, can control cell proliferation, survival, and differentiation. CD32 is 
a member of the Fc-gamma receptor family and is mainly found on immune cells. 
Transplantation of CD34+CD38−CD25+ cells and CD34+CD38−CD32+ cells into NO/
SCID mice can trigger leukemia and resistance to cytarabine. It has been reported 
that overexpression of CD25 in AML cells may be caused by the activation of STAT5 
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and MYC [29, 30]. Gönen et al. analyzed the correlation between the expression 
of CD25 (IL-2 receptor alpha) and prognosis in 657 patients with primary AML 
(≤60 years old); they concluded that CD25 can be used as a biomarker for poor 
prognosis of AML [31]. Cerny et al. also indicated that CD25 expression can be used 
as an indicator to predict early treatment failure in AML [32].
3. LSCs are the source of treatment resistance
The most fundamental reason for the relapse of AML is the existence of LSCs. It 
is necessary to investigate the key mechanisms of resistance of LSCs to the current 
treatment strategy for effective clearance of LSC.
3.1 LSCs are mostly in the G0 quiescent phase
Dean et al. showed that 96% of LSCs are in the G0 phase of the cell cycle [33]. 
Chemotherapeutic drugs acting on the cell cycle or on rapidly differentiating cells can 
inhibit only differentiated mature leukemia cells, while LSCs in the G0 phase cannot 
be completely inhibited because they do not divide. Once they are properly stimu-
lated to re-enter the cell cycle, they will continue to proliferate and differentiate into 
daughter leukemia cells, thus causing recurrence. According to some studies, LSCs are 
much less sensitive to daunorubicin and cytarabine than differentiated leukemia cells.
3.2 LSCs highly express multidrug resistance genes and proteins
The expression of multidrug resistance genes on the surface of LSCs can induce 
the production of various membrane transporters that can pump a variety of 
chemotherapeutic drugs out of the cell, which results in lowering the concentra-
tion of the drug in the cancer cells. The ABC membrane transporter plays a pivotal 
role in this drug efflux process. The ABC transporter, namely the ATP-binding 
cassette transporter, has an ATP-dependent drug-release function [34]. The most 
representative multidrug resistance genes are ABCB1, ABCC1, and ABCG2, which 
encode P-glycoproteins (P-gp, P-170, and MDR1), multidrug resistance protein 
(MRP), and breast cancer resistance protein (BCRP), respectively. BCRP is pref-
erentially expressed in CD34+CD38− LSCs. The intracellular drug concentration 
after BCRP inhibition is increased, but it is much lower than that of cells expressing 
only BCRP. Therefore, it is indicated that the drug resistance of LSC is related to the 
interaction of multiple drug resistance proteins. Some other reports have revealed 
that LSC has higher MDR1, MRP, BCRP, and lung resistance related protein (LRP) 
expression relative to HSC, thus giving LSC a stronger drug resistance advantage. 
The high expression of multidrug resistance gene in LSCs is the main mechanism by 
which LSCs exhibit primary resistance to chemotherapeutic drugs [35, 36].
3.3 LSC display higher self-renewal ability
Hope et al. proved that LSCs have self-renewal ability, which is one of the most 
prominent features of CSCs [37]. The self-renewal ability of LSCs may be one of 
the key factors that promote the development and metastasis of leukemia, and the 
molecular regulation mechanism is very complicated. Bmi-1 is a member of the 
PcG (polycomb group) transcriptional repressor family and is an essential factor 
in maintaining HSC self-renewal. Raffel et al. showed that miR-126 overexpression 
renders AML cells more resistant to standard chemotherapy and that treatment 
of primary AML cells results in the enrichment of LSC-like cells with increased 
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miR-126 levels [38]. Moreover, leukemic cells with high miR-126 expression were 
selected in refractory patients after induction chemotherapy, thus correlating high 
miR-126 levels to LSCs and therapy resistance. miR-126 knockdown leads to the 
expansion of HSCs but impaired maintenance of LSCs, and its overexpression 
promotes LSC self-renewal, which is inhibited in HSCs [39, 40]. In addition, all 
genes and signaling pathways that contribute to HSC self-renewal may be involved 
in LSCs, such as Wnt, Notch, HOX, and Shh. Recent studies have revealed that the 
activation of the Shh signaling pathway in LSCs by upregulation of SMO is essential 
for LSC survival maintenance [41, 42].
3.4 The special microenvironment (niche)
The receptors CXCR4 on the LSC membrane and CXCL12 in the bone mar-
row microenvironment are required for LSC to maintain dormancy, self-renewal, 
differentiation, growth, and homing. However, targeted therapy for the niche will 
enhance the expression of the drug pump MDR1, which induced LSC insensitive to 
therapy and failed to achieve the goal of reversing its resistance [43].
3.5 Multiple signaling pathway abnormalities
Recent studies have demonstrated that abnormal activation of multiple signal-
ing pathways is one of the key mechanisms of LSC multidrug resistance, such as 
Sonic Hedgehog, Bmi-1, Nocth, and WNT. Among these pathways, the abnormality 
of Hedgehog (Hh) pathway is closely related to CSC resistance, such as increased 
endogenous synthesis of ligand protein Hh, loss of PCTH activity, inhibition of 
smoothened (SMO) signaling protein, mutation of SUFU, and overexpression of 
the transcription factor GLI1, thus regulating the downstream target gene and 
participating in the maintenance of stem cell proliferation, which are related to 
multiple hallmarks of tumor cell resistance [44, 45]. Studies have revealed that 
Hh signaling is abnormally activated in LSCs, GLI1 can induce endogenous BCL-2 
expression, and the Hh pathway also up-regulates BCL-2 by activating PI3K/AKT, 
thus leading to apoptotic disorder and drug resistance of LSCs.
4. The role of LSCs in tumor metastasis and invasion
CSCs are thought to be the seed of tumor metastasis. CSCs that particularly 
express C-X-C chemokine receptor type 4 (CXCR4) preferentially disseminate [46]. 
The specific ligand for the CXCR4 chemokine receptor is termed matrix-derived 
factor-1 (SDF-1, also known as CXCL12). Both CXCR4 and SDF-1 are expressed in 
various tissues and cell types and regulate cell migration [47]. The SDF-1/CXCR4 
axis is also involved in the migration of CSCs [48]. SDF-1 is a homeostatic chemo-
kine secreted by stromal cells and is released into the interstitial space [49]. On 
the one hand, SDF-1 exerts effects through its unique physiologic cognate receptor 
CXCR4, which is known to mediate chemotaxis, hematopoiesis, angiogenesis, and 
tumor spread and metastasis. On the other hand, it also acts in a paracrine fashion 
on cells in the local microenvironment to stimulate directional migration of hema-
topoietic and nonhematopoietic normal and malignant cells [50–52]. Li et al. found 
that HERG K+ channels were widely expressed in primary leukemic cells but not in 
normal lymphocytes [53, 54]. Blocking HERG K+ channels by applying its specific 
inhibitor in hematopoietic cell lines and primary leukemic cells significantly 
reduced the migration of leukemic cells induced by SDF-1; this indicated a role for 
HERG K+ channels in the progression of leukemia.
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Currently, there is a lack of direct evidence linking LSCs to metastasis. There 
are some sporadic reports that LSCs may play a role in metastasis. In patients with 
AML, low levels of CXCR4 expression have been shown to be associated with better 
prognosis, longer recurrence-free period, and overall survival. It has also been 
suggested that CXCR4 is an independent prognostic predictor of disease recur-
rence and survival [55]. Another study has shown that overexpression of C-myc, 
Bmi-1, Oct4, and Nanog in precancerous and cancerous cells may initiate oncogenic 
epithelial-mesenchymal transition and tumorigenesis, which plays important roles 
in the genesis of CSCs, malignant tumor initiation and progression, cancer metas-
tasis, and drug resistance [56]. Compared with the parental cells, chemotherapy-
resistant MOLT4+ cells expressed much higher levels of the stem cell surface marker 
CXCR4. It was found that the expression of CXCR4, related to tumor cell homing 
and migration, was significantly higher in MOLT4+ cells than in MOLT4− cells. In 
addition, hMDSCs-MOLT4 cells seem to have a strong invasive potential in vivo, as 
demonstrated by strong interstitial and vascular tissues in tumor tissue sections.
It was confirmed that the niche was involved in metastasis. With respect to 
HSCs, two distinct niches have been defined: the osteoblastic niche and the vas-
cular niche [57–59]. Tabe et al. hypothesized the presence of a “metastatic niche” 
that facilitates the survival, proliferation, and metastasis of LSCs [60]. Yang et al. 
demonstrated that vascular endothelial growth factor receptor 1 (VEGFR1) was 
involved in the initiation of a premetastatic niche and that cells expressing VEGFR1 
home to tumor-specific premetastatic sites and form cellular clusters before the 
arrival of tumor cell clusters [61]. They can alter the local microenvironment and 
lead to the activation of integrins and chemokines. After treatment with anti-
VEGFR1 antibodies, the supportive premetastatic cell clusters were abolished and 
metastasis was prevented, which indicated the importance of a metastatic niche.
5. The role of LSCs in tumor proliferation and anti-apoptosis
Various signaling pathways that stimulate proliferation or inhibit apoptosis are 
known to aberrant activate LSCs.
5.1 Hedgehog pathway
The Hh pathway is a highly conserved pathway that regulates the proliferation, 
migration, and differentiation of cells during development [62, 63]. Three distinct 
ligands, namely Sonic (Shh), Indian (Ihh), and Desert (Dhh) Hedgehog, exist in 
humans. Upon ligand binding to the receptor pat (Ptch), inhibition of smooth-
ened (Smo) receptor is relieved. Smo then activates members of the Gli family of 
zinc-finger transcription factors, translocating them to the nucleus to regulate the 
transcription of Hh target genes including Gli1, Gli2, and Ptch, and regulators of 
cell proliferation and survival [64–66].
The Hh pathway promotes cell proliferation mainly by regulating cell cycle. 
Its regulation mechanism is as follows [67]: (1) Cyclin D1 and cyclin D2 act as 
downstream target genes for the transcription factor GLI1 and are involved in cell 
cycle G1 to S phase transformation; (2) PTCH regulates the activity of cyclin B, 
which is part of the mitosis promoting factor (MPF) compound. MPF is required 
for cell entry from the G2 phase to the M phase; and (3) SMO proteins block cellular 
dormancy by modulating P21, a cyclin-dependent inhibitory protein.
The Hh signaling pathway regulates apoptosis mainly through the following 
mechanisms: (1) Regulate the activity of the BCL-2 family. The BCL-2 family is 
divided into anti-apoptotic proteins (such as BCL-2, BCL-XL, and MCL-1) and 
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pro-apoptotic proteins (such as BAX, BAD, and BAK). The ratio between the two 
types of proteins will directly affect the stability of the mitochondrial membrane 
and is the most important regulator of the mitochondrial apoptosis pathway. 
Overexpression of BCL-2, an increase in the ratio of BCL-2 to BAD, leading to 
defects in mitochondrial apoptosis, is one of the important mechanisms for LSC 
multidrug resistance and poor prognosis of AML [68]. BCL-2 is the target gene 
downstream of the Hh pathway, and Hh pathway blockers can induce apoptosis 
by downregulating BCL-2 [69]. Kobune et al. found that cyclopamine induces 
apoptosis of drug-resistant CD34+ AML cells by downregulating BCL-2 and makes 
them sensitive to Ara-C [70]. MCL1 has also emerged as a mechanism of resistance 
to apoptosis and to BCL-2/BCL-XL inhibitors, and therefore, it is considered as a 
potential therapeutic target [71]. (2) Regulation of tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) mediated apoptosis. TRAIL-R3 is a blank recep-
tor that lacks a functional death region and is highly expressed in CD34+CD38− 
LSCs; the downregulation of TRAIL-R3 increases apoptosis [72]. (3) Regulation of 
FAS protein express in the death receptor pathway. Studies have found that the Hh 
pathway inhibitor GDC-0449 promotes tumor stem cell apoptosis by upregulating 
FAS protein [73].
5.2 NF-κB pathway
NF-κB is a significant transcriptional activator located upstream of the IRF-1 
gene. It is aberrantly activated by LSCs. NF-κB not only inhibits apoptosis but also 
regulating the expression of cytokine genes. Furthermore, apoptosis can be inhib-
ited by inducing and upregulating antiapoptotic genes. Therefore, NF-κB plays an 
essential role in maintaining LSC growth and survival. Inhibition of this signaling 
pathway not only promotes LSC apoptosis but also enhances the sensitivity of 
LSCs to chemotherapeutic drugs [74, 75]. At present, the targeted drugs for NF-κB 
are mainly proteasome inhibitors MG-132 and Bortezomib (VELCADE, PS-341), 
which can better target LSCs without any significant effect on normal HSC. It was 
reported that PTL can specifically induce apoptosis of LSCs by inhibiting NF-κB 
activity. At present, the PTL analog DMAP has been developed, and its experimen-
tal effect is remarkable [76, 77].
5.3 PI3K/Akt pathway
The PI3K/Akt pathway is an intracellular pathway that plays a critical role in 
apoptosis and cancer, whose components are often altered in cancer, leading to 
dysregulated apoptosis and chemoresistance [78]. Chen et al. demonstrated that 
the PI3K inhibitor LY294002 can directly target LSCs without adverse reactions 
to normal HSCs, and they found that PI3K and NF-κB may coexist in the same 
signaling pathway [79]. Further, it has been reported that the mammalian target of 
rapamycin (mTOR) is a substrate for PI3K that regulates the survival of LCSs after 
etoposide treatment. Mise et al. showed that the inhibitory effect of rapamycin 
on mTOR significantly reduced the survival rate of AML cells, and rapamycin 
enhanced the effect of etoposide on these cells [80]. It is found that PTEN that 
negatively regulates the PI3K pathway and is essential for maintaining normal 
hematopoiesis [81]. However, PTEN deletion has no significant effect on HSC dif-
ferentiation survival, while PTEN deletion in LSCs can lead to the production and 
proliferation of LSCs. In addition, rapamycin, an inhibitor of the PI3K pathway 
downstream regulator of mTOR was found to inhibit LSCs and protect against 
normal HSC failure.
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6. Treatment avenue for LSC
6.1 Niche of LSCs
Niche is involved in stem cell self-renewal, survival, chemotherapy tolerance, 
and metastasis of leukemia cells [82]. In the mice model, it was found that the 
homing of HSCs to the bone marrow is regulated by chemokine CXCL12 expressed 
in mesenchymal stem cells, and its receptor is CXCR4 [83]. Inhibition of CXCL12-
CXCR4 interaction helps to reduce chemotaxis, thus affecting the movement, adhe-
sion, and metastasis of LSCs. In vitro studies have shown that the anti-leukemia 
active peptide CXCR4 inhibitor LY2510924, as a single agent or in combination che-
motherapy, can rapidly and permanently destroy the CXCL12-CXCR4 axis, thereby 
inhibiting the proliferation of AML cells and leading to apoptosis [84]. Fully human 
IgG4 monoclonal antibody BMS-936564 against CXCR4 showed high safety and 
antitumor activity in relapsed and refractory patients with AML [85]. However, 
because of the similar biological properties of LSCs and HSCs, the non-selection of 
related inhibitors has become another major clinical problem.
In addition to participating in the hematopoietic function, the bone marrow 
niche is also an important place for the presence of immune cells. There is a group 
of activated leukemia-specific immune cells in leukemia bone marrow, and regula-
tory T cell (Treg) is one of the important members [86]. Fujisaki et al. found that 
hematopoietic stem/progenitor cells and Treg can coexist on the endosteum of 
murine bone marrow, and HSPC disappears shortly after Treg cell depletion [87]. 
This experiment successfully demonstrated the involvement of Treg cells in the 
formation of bone marrow niche. Treg is a dynamic cell population that regulates 
the immune response. Stem cells evade immune surveillance by recruiting Treg cells 
and using their regulatory functions [88]. Therefore, it is speculated that these cells 
will likely become new targets for eliminating LSCs (Figure 2) [89].
6.2 LSCs-related signaling pathways
Leukemia is characterized by selective overgrowth of LSCs and interferes with 
the differentiation of HSCs. Chemotherapy kills rapidly dividing cancer cells, 
but does not eliminate reservoirs of LSCs that cause relapse. LSCs have a variety 
of regulatory abnormal signaling pathways, including WNT/β-catenin, JAK/
STAT, PI3K/AKT, RAS, NF-κB, and Notch. WNT is involved in the maintenance of 
properties of LSCs. Riether et al. discovered that tyrosine kinase inhibitors induced 
CD70 expression on LSCs during targeted drug therapy, while CD70 inhibited 
WNT/β-catenin signaling pathway [90]. STAT is an important transcription factor 
regulating cell growth, proliferation, and inhibition of apoptosis. Activation of the 
JAK/STAT signaling pathway is associated with sustained activation of the proto-
oncogene AHI-1 in CD34 cells, regulating CML-LSC autonomous growth in vitro 
and inducing leukemia [91].
In recent years, studies on micro-RNA and transcription factors in leukemia 
patients have become increasingly mature. For example, the transcription factor 
MYC can inhibit the expression of the shared target gene FLT3 by miR-15a-5p, and 
FLT3 plays a crucial role in activating the STAT5A pathway and promoting tumor 
cell proliferation [92, 93], but its specific mechanism of influence on the develop-
ment of tumor remains to be further investigated. Targeted drugs in mounting 
numbers for LSCs signaling pathways are being developed, but most of them are 
still in the stage of animal experiments, and more research is needed to determine 
the safety and efficacy in humans.
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6.3 Cell cycle of LSCs
In patients with drug resistance, most of their LSCs are in the quiescent phase 
(G0 phase) and therefore cannot be effectively eliminated by chemotherapy. 
Hence, some people consider that LSCs in stationary phase can be eliminated by 
two-step method: (1) Stimulate LSCs from the G0 phase into the cell cycle prolif-
eration and then use specific tumor-targeted therapeutic drugs to eliminate LSCs 
and (2) Let LSCs stay in the G0 phase. It is worth noting that although the cells 
in the G0 phase are dormant, they have the ability to proliferate; thus, this can 
only delay survival and avoid recurrence. Experiments in vitro have shown that 
cyclin-dependent kinase (CDK6) can be involved in the regulation of cell cycle, 
and inhibition of CDK6 may cause leukemia stem cells to dormant and inhibit cell 
proliferation [94].
6.4 Immunophenotype of LSCs
Several immunophenotypes of LSCs have been identified, such as CD34, 
CD38, CD123, CD117, CD71, CD44, HLA-DR, TIM3, CLL-1, CD96, CD47, CD32 
and CD25. Although these surface molecules are not expressed in all LSCs, their 
high expression may lead to a significant deterioration of the disease prognosis. It 
is also because of the difference in markers and functions between LSCs and HSCs 
that targeted therapy for leukemia stem cells is possible. CD33 is the first AML 
targeted therapeutic antigen approved by the US FDA, which is highly expressed 
in AML but not in normal HSCs. The monoclonal anti-tumor drug Gemtuzumab 
ozogamicin, consisting of the CD33 antibody, hP67.6, and the cytotoxic drug, is 
Figure 2. 
The niche of leukemic stem cell. The niche provides support for self-renewal, quiescence, homing, engraftment, 
and proliferative potential for HSCs. LSCs may impair the function of the normal HSC niche. In addition, 
LSCs can infiltrate these niches and may hijack these normal homeostatic processes.
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a good candidate for selective killing of CD33+ LSCs [95]. In addition, in recent 
years, tumor-specific chimeric antigen receptor T-cell immunotherapy (CART) 
against CD33+ cells has become increasingly popular [96]. Busfield et al. detected 
that the anti-CD123 monoclonal antibody CSL362 has a good tumor cell killing 
effect in the AML mouse model [22].
Although the current monoclonal antibodies against the LSCs phenotype have 
achieved initial clinical success, it is undeniable that LSCs are diverse among 
different patients, and even in the same individual, the phenotypic differences 
are quite different. This brings new challenges to clinical treatment. Moreover, 
studies have shown that in patients with newly diagnosed AML, the distribution 
of LSCs is uniform and the number is small, but once the patient relapses after 
chemotherapy, the number of LSCs can be significantly increased, and some new 
phenotypes appear [97]. The phenotypic changes in LSCs at different stages of 
the same patient’s disease also lead to difficulties in clinical application of this 
targeted LSC immunophenotypic treatment strategy. Therefore, the current 
targeted therapy based on this strategy is still in the exploration stage, and the 
development of related drugs is significantly limited due to the plasticity of the 
immunophenotype of LSCs.
7. Summary
LSCs play an important role in the origin, recurrence, and drug resistance of 
leukemia. Although the current research on LSCs has made some progress, the 
biological characteristics of LSCs and its mechanism in the pathogenesis of leuke-
mia remain unclear, and the treatment strategy for targeted clearance of LSCs is 
still in its infancy. Therefore, clarifying its biological characteristics and developing 
drugs for targeted therapy of LSCs is an important direction for leukemia research 
in future.
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